Interaction of clopidogrel and statins in secondary prevention after cerebral ischaemia - a randomized, double-blind, double-dummy crossover study.

Published on Nov 1, 2014in British Journal of Clinical Pharmacology3.74
· DOI :10.1111/BCP.12416
Timo Siepmann17
Estimated H-index: 17
(TUD: Dresden University of Technology),
Denise Heinke1
Estimated H-index: 1
(TUD: Dresden University of Technology)
+ 8 AuthorsGeorg Gahn16
Estimated H-index: 16
Aims Variability in responsiveness to clopidogrel is a clinical problem in secondary prevention after cerebral ischaemia which has been suggested to be linked to competitive metabolization of clopidogrel and cytochrome P450 (CYP) 3A4-oxidated statins such as simvastatin. We assessed the hypothesis that simvastatin, in contrast to CYP 2C9-metabolized fluvastatin, reduces clopidogrel-mediated platelet inhibition. Methods We performed a randomized, double-blind, double-dummy, two period crossover study in 13 patients with cerebral ischaemia (8F, 5 M), aged 64.1 ± 8.0 years (mean ± SD). After a 14 day period in which all patients received 75 mg clopidogrel day−1, patients additionally received either 20 mg simvastatin day−1 or 80 mg fluvastatin day−1 for 14 days. Regimens were crossed over after a 14 day wash-out period and switched regimens were continued for another 14 days. Platelet aggregation, clopidogrel active metabolite (CAM) plasma concentrations and routine laboratory parameters including prothrombin time (PT) Quick percent value were assessed at baseline and following each treatment phase. Results Clopidogrel reduced platelet aggregation in all patients as expected. Platelet aggregation and CAM plasma concentrations were unaltered when simvastatin or fluvastatin was added to clopidogrel. Simvastatin decreased PT Quick percent value (decrease from 109 ± 10.5% to 103 ± 11%, P < 0.05) when combined with clopidogrel but there was no such change following treatment with fluvastatin and clopidogrel. Conclusions Our data indicate that treatment with CYP 3A4-metabolized simvastatin does not jeopardize clopidogrel-mediated inhibition of platelet aggregation. After co-administration of simvastatin and clopidogrel we observed a decrease in the PT Quick percent value which could be due to simvastatin-induced reduction of activity of prothrombin fragment 1 + 2.
📖 Papers frequently viewed together
180 Citations
6 Authors (Iris Müller, ..., Meinrad Gawaz)
128 Citations
#1Stuart A. Scott (ISMMS: Icahn School of Medicine at Mount Sinai)H-Index: 49
#2Katrin Sangkuhl (Stanford University)H-Index: 29
Last. Alan R. Shuldiner (UMB: University of Maryland, Baltimore)H-Index: 124
view all 10 authors...
Cytochrome P450 (CYP)2C19 catalyzes the bioactivation of the antiplatelet prodrug clopidogrel, and CYP2C19 loss-of-function alleles impair formation of active metabolites, resulting in reduced platelet inhibition. In addition, CYP2C19 loss-of-function alleles confer increased risks for serious adverse cardiovascular (CV) events among clopidogrel-treated patients with acute coronary syndromes (ACSs) undergoing percutaneous coronary intervention (PCI). Guideline updates include emphasis on appropr...
627 CitationsSource
#1Pertti J. Neuvonen (HYKS: Helsinki University Central Hospital)H-Index: 105
Abstract HMG-CoA reductase inhibitors (statins) can cause skeletal muscle toxicity; the risk of toxicity is elevated by drug interactions and pharmacogenetic factors that increase the concentration of statins in the plasma. Statins are substrates for several membrane transporters that may mediate drug interactions. Inhibitors of the organic anion transporting polypeptide 1B1 can decrease the hepatic uptake of many statins, as well as the therapeutic index of these agents. Potent inhibitors of cy...
101 Citations
#1Cathie Sudlow (Edin.: University of Edinburgh)H-Index: 68
#2Gillian MasonH-Index: 1
Last. Graeme J. Hankey (RPH: Royal Perth Hospital)H-Index: 149
view all 5 authors...
Aspirin is the most widely studied and prescribed antiplatelet agent for preventing serious vascular events, reducing the odds of such events among high vascular risk patients by about a quarter. Thienopyridine derivatives inhibit platelet activation by a different mechanism and so may be more effective.To determine the effectiveness and safety of thienopyridine derivatives (ticlopidine and clopidogrel) versus aspirin for preventing serious vascular events (stroke, myocardial infarction (MI) or ...
45 CitationsSource
#1Makoto Takahashi (Daiichi Sankyo)H-Index: 3
#2Henrianna PangH-Index: 2
Last. Atsushi Kurihara (Daiichi Sankyo)H-Index: 23
view all 5 authors...
Abstract A quantitative method for the determination of clopidogrel active metabolite (AM) in human plasma was developed and validated using liquid chromatography–tandem mass spectrometry (LC–MS/MS). Clopidogrel AM contains a thiol group, thus requiring stabilization in biological samples. The alkylating reagent 2-bromo-3′-methoxyacetophenone was used to stabilize clopidogrel AM in blood. An analog of the derivatized clopidogrel AM was used as the internal standard (IS). The derivatized samples ...
109 CitationsSource
#1Dominick J. Angiolillo (UF: University of Florida)H-Index: 106
#2Antonio Fernández-Ortiz (Hospital Clínico San Carlos)H-Index: 67
Last. Marco A. Costa (UF: University of Florida)H-Index: 65
view all 7 authors...
Antiplatelet therapy is the cornerstone of treatment for patients with acute coronary syndromes and/or undergoing percutaneous coronary interventions. Clopidogrel, in combination with aspirin, is currently the antiplatelet treatment of choice for prevention of stent thrombosis, and clinical trials have shown that, in high-risk patients, prolonged dual antiplatelet treatment is more effective than aspirin alone in preventing major cardiovascular events. However, despite the use of clopidogrel, a ...
837 CitationsSource
#1Mohammad J. Tafreshi (MWU: Midwestern University)H-Index: 8
#2Laura G Zagnoni (MWU: Midwestern University)H-Index: 1
Last. Elmer J Gentry (BMS: Bristol-Myers Squibb)H-Index: 1
view all 3 authors...
Background. The 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors (statins) and clopidogrel are frequently used in the treatment of patients with various cardiovascular disorders. The possibility of a drug-drug interaction between certain statins and clopidogrel has been extensively investigated in the literature recently. Investigators have proposed that the use of statins that are metabolized by the cytochrome P450 (CYP) system may diminish the conversion of clopidogrel to its active ...
10 CitationsSource
#1Sora Ludwig (UM: University of Manitoba)H-Index: 18
#2Sudharshan Dharmalingam (UM: University of Manitoba)H-Index: 2
Last. Garry X. Shen (UM: University of Manitoba)H-Index: 19
view all 12 authors...
Abstract Simvastatin, a widely used 3-hydroxy-3-methylglutaryl-CoA (HMG-CoA) reductase inhibitor, effectively reduced cardiac death and ischemic events in patients with coronary heart disease (CHD) and diabetes mellitus (DM). The mechanism of cardiovascular benefits of statins in DM remains unclear. We examined how simvastatin influences the levels of several in vivo markers for coagulation and fibrinolysis in 26 Type 2 DM patients. The diabetic patients received 20mg/day of simvastatin up to 12...
32 CitationsSource
#1Sophie Ziegler (Medical University of Vienna)H-Index: 18
#2Martin Schillinger (Medical University of Vienna)H-Index: 73
Last. Christine Mannhalter (Medical University of Vienna)H-Index: 75
view all 12 authors...
Background and Purpose— There is considerable variability in the antiplatelet effects of the thienopyridine agent “clopidogrel.” We tested for an association of gene sequence variations in P2Y12 and occurrence of neurological adverse events in patients with symptomatic peripheral artery disease (PAD) during clopidogrel treatment. Methods— We studied 137 patients undergoing antiplatelet therapy with clopidogrel and 336 patients with aspirin for the occurrence of neurological events (ischemic stro...
79 CitationsSource
#1Debabrata Mukherjee (UM: University of Michigan)H-Index: 78
#2Eva Kline-Rogers (UM: University of Michigan)H-Index: 51
Last. Kim A. EagleH-Index: 142
view all 5 authors...
Objective: To assess a clinically significant interaction between cytochrome P450 3A4 (CYP3A4) metabolised statin and clopidogrel. Design: Prospective single centre cohort study. Setting: Academic teaching hospital in the USA. Patients: 1651 patients presenting with acute coronary syndromes between January 1999 and February 2003 were studied. Data on baseline demographics, co-morbidities, and in-hospital management were collected. Main outcome measure: Association of CYP3A4 metabolised statin an...
58 CitationsSource
#2Mark G. MideiH-Index: 1
Last. Charles H. HennekensH-Index: 135
view all 11 authors...
Background Some, but not all, post hoc analyses have suggested that the antiplatelet effects of clopidogrel are inhibited by atorvastatin. We sought to address this issue prospectively by performing serial measurements of 19 platelet characteristics using conventional aggregometry, rapid analyzers, and flow cytometry. Methods The Interaction of Atorvastatin and Clopidogrel Study (Interaction Study) was designed for patients undergoing coronary stenting. All patients (n = 75) received 325 mg of a...
148 CitationsSource
Cited By6
#1Isabella Damiani (University of Milan)H-Index: 1
#2Alberto Corsini (University of Milan)H-Index: 60
Last. Stefano Bellosta (University of Milan)H-Index: 37
view all 3 authors...
Persons aged more than 65 years may be more prone to suffer from chronic diseases and comorbidities (as demonstrated by the recent COVID-19 pandemics) and are treated with multiple concomitant medi...
3 CitationsSource
#1Ke An (SEU: Southeast University)H-Index: 2
#2Rong Huang (SEU: Southeast University)H-Index: 13
Last. Shaohua Wang (SEU: Southeast University)H-Index: 17
view all 7 authors...
Background Combination of statins and clopidogrel is frequently administered in patients with coronary artery disease (CAD). They are mainly activated and eliminated in the liver by cytochrome P450 isoenzyme 3A4 (CYP3A4). The aim was to clarify whether the coadministration of clopidogrel and statins attenuate respective efficacy.
4 CitationsSource
OBJECTIVES: Dual antiplatelet therapy (DAPT) with aspirin and clopidogrel reduces the risk for recurrent cardiovascular events after acute coronary syndrome (ACS). However, there is significant variation in response to DAPT that may be influenced by both genetic and nongenetic factors. This study aimed to assess the effect of genetic polymorphisms in PON-1, PEAR-1, P2Y12, CES1, and CYP2C19, along with clinical, demographic, and social factors, on variation in response to DAPT in Egyptians. PARTI...
7 CitationsSource
#1Ying Zhang (CAS: Chinese Academy of Sciences)H-Index: 36
#2Xinling Jia (SHU: Shanghai University)H-Index: 2
Last. Jingye WangH-Index: 1
view all 7 authors...
The mechanisms by which Shaoyao-Gancao decoction (SGD) inhibits the production of inflammatory cytokines in serum and brain tissue after cerebral ischemia-reperfusion (CI-RP) in rats were investigated. A right middle cerebral artery occlusion was used to induce CI-RP after which the rats were divided into model (), SGD (), clopidogrel () and sham operated () groups. The Bederson scale was used to evaluate changes in behavioral indices. The levels of IL-1β, TNF-α, MCP-1, IL-10, RANTES, VEGF, and ...
9 CitationsSource
#1Matti K. Itkonen (UH: University of Helsinki)H-Index: 6
#2Aleksi Tornio (UH: University of Helsinki)H-Index: 19
Last. Janne T. Backman (UH: University of Helsinki)H-Index: 77
view all 6 authors...
Simvastatin and clopidogrel are commonly used together in the treatment of cardiovascular diseases. Organic anion transporting polypeptide (OATP) 1B1 activity markedly affects the hepatic uptake of simvastatin acid, whereas both simvastatin and simvastatin acid are sensitive to changes in cytochrome P450 3A4 activity. Clopidogrel and its metabolites inhibit OATP1B1 and CYP3A4 in vitro. We studied the effect of clopidogrel on the pharmacokinetics of simvastatin in a randomized crossover study. Tw...
19 CitationsSource